Nurofen tab. p / o 200mg No. 20
Package quantity, pcs:
8
ten
twenty
Category
Pain relievers
,
Migraine
,
Pain and fever
Scope of the drug
General
Release form
Tablet
Manufacturer country
Great Britain
Package quantity, pcs
twenty
Release form, composition and packaging
?
Coated tablets of white or off-white color, round, biconvex, with black Nurofen" overprinting on one side
on a cross-section of a tablet, the core is white or almost white, the shell is white or almost white.
1 tab.
ibuprofen 200 mg
croscarmellose sodium - 30 mg, sodium lauryl sulfate - 0.5 mg, sodium citrate dihydrate - 43.5 mg, stearic acid - 2 mg, colloidal silicon dioxide - 1 mg.
Shell composition: sodium carmellose - 0.7 mg, talc - 33 mg, acacia gum - 0.6 mg, sucrose - 116.1 mg, titanium dioxide - 1.4 mg, macrogol 6000 - 0.2 mg, black ink [Opakod S-1-277001] (shellac - 28.225%, iron dye black oxide (E172) - 24.65%, propylene glycol - 1.3%, isopropanol * - 0.55%, butanol * - 9.75%, ethanol * - 32.275%, purified water * - 3.25%).
* solvents evaporated after the printing process.
6 pcs.
- blisters (1) - cardboard packs.
6 pcs.
- blisters (2) - cardboard packs.
8 pcs.
- blisters (1) - cardboard packs.
8 pcs.
- blisters (2) - cardboard packs.
10 pieces.
- blisters (1) - cardboard packs.
10 pieces.
- blisters (2) - cardboard packs.
10 pieces.
- blisters (3) - cardboard packs.
12 pcs.
- blisters (1) - cardboard packs.
12 pcs.
- blisters (2) - cardboard packs.
12 pcs.
- blisters (3) - cardboard packs.
12 pcs.
- blisters (4) - cardboard packs.
12 pcs.
- blisters (8) - cardboard packs.
pharmachologic effect
NSAIDs.
Has a fast directed action against pain (analgesic), antipyretic and anti-inflammatory action.
The mechanism of action of ibuprofen, a propionic acid derivative, is due to inhibition of the synthesis of prostaglandins - mediators of pain, inflammation and hyperthermic reaction.
Indiscriminately blocks COX-1 and COX-2, as a result of which it inhibits the synthesis of prostaglandins.
In addition, ibuprofen reversibly inhibits platelet aggregation.
The analgesic effect of the drug lasts up to 8 hours.
Pharmacokinetics
Absorption and distribution Absorption - high, quickly and almost completely absorbed from the gastrointestinal tract. After taking the drug on an empty stomach, Cmax of ibuprofen in blood plasma is reached after 45 minutes. Taking the drug with food can increase the time to reach Cmax up to 1-2 hours. Plasma protein binding is 90%. It slowly penetrates into the joint cavity, remains in the synovial fluid, creating higher concentrations in it than in the blood plasma. In the cerebrospinal fluid, lower concentrations of ibuprofen are found in comparison with blood plasma. In limited studies, ibuprofen has been found in breast milk at very low concentrations. Metabolism and excretion After absorption, about 60% of the pharmacologically inactive R-form is slowly transformed into the active S-form. It is metabolized in the liver.It is excreted by the kidneys (unchanged - no more than 1%) and, to a lesser extent, with bile. T1 / 2 - 2 hours
Indications for use
- headache
- migraine
- toothache
- neuralgia
- myalgia
- back pain
- rheumatic pains
- joint pain
- algodismenorrhea
- fever with flu and ARVI.
Contraindications for use
- complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses, and intolerance to acetylsalicylic acid or other NSAIDs (including history)
- erosive and ulcerative diseases of the gastrointestinal tract (including peptic ulcer and duodenal ulcer, Crohn's disease, ulcerative colitis) or ulcerative bleeding in the active phase or in history (two or more confirmed episodes of peptic ulcer or ulcerative bleeding)
- a history of bleeding or perforation of gastrointestinal ulcers, provoked by the use of NSAIDs
- severe liver failure or liver disease in the active phase
- renal failure of severe severity (CC < 30 ml / min)
& m
Dosage
200mg
Structure
One film-coated tablet contains the active ingredient - ibuprofen 200 mg
excipients: croscarmellose sodium 30 mg, sodium lauryl sulfate 0.5 mg, sodium citrate dihydrate 43.5 mg, stearic acid 2 mg, colloidal silicon dioxide 1 mg.
shell composition: sodium carmellose 0.7 mg, talc 33 mg, acacia gum 0.6 mg, sucrose 116.1 mg, titanium dioxide 1.4 mg, macrogol 6000 0.2 mg, black ink [Opakod S-1-277001 ] (shellac 28.225%, iron dye black oxide (E172) 24.65%, propylene glycol 1.3%, isopropanol * 0.55%, butanol * 9.75%, ethanol * 32.275%, purified water * 3.25% ).
* Solvents evaporated after the printing process.
Indications
headache
migraine
toothache
neuralgia
myalgia
back pain
rheumatic pains
joint pain
algodismenorrhea
fever with flu and ARVI.
INN / Active ingredient
Ibuprofen
Storage conditions and periods
At a temperature not higher than 25 degrees.
Expiration date: 3 years
Contraindications
complete or incomplete combination of bronchial asthma, recurrent polyposis of the nose and paranasal sinuses, and intolerance to acetylsalicylic acid or other NSAIDs (including in history)
erosive and ulcerative diseases of the gastrointestinal tract (including peptic ulcer and duodenal ulcer, Crohn's disease, ulcerative colitis) or ulcerative bleeding in the active phase or in history (two or more confirmed episodes of peptic ulcer or ulcerative bleeding)
a history of bleeding or perforation of a gastrointestinal ulcer, provoked by the use of NSAIDs
severe liver failure or active liver disease
renal failure of severe severity (CC < 30 ml / min)
confirmed hyperkalemia
severe heart failure (NYHA class IV)
decompensated heart failure
period after coronary artery bypass grafting
cerebrovascular or other bleeding
hemophilia and other blood clotting disorders (including hypocoagulation)
hemorrhagic diathesis
III trimester of pregnancy
children under 6 years old
fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase deficiency
hypersensitivity to ibuprofen and other components of the drug.
With caution, the drug should be prescribed with the simultaneous use of other NSAIDs a history of a single episode of gastric ulcer and duodenal ulcer and duodenal ulcer or gastrointestinal ulcer bleeding gastritis, enteritis, colitis, Helicobacter pylori infection, ulcerative colitis bronchial asthma or allergic diseases in an exacerbation stage or in history (bronchospasm may develop) systemic lupus erythematosus or mixed connective tissue disease (Sharp's syndrome) - increased risk of aseptic meningitis chickenpox renal failure, incl. with dehydration (CC less than 30-60 ml / min), nephrotic syndrome liver failure, liver cirrhosis with portal hypertension, hyperbilirubinemia arterial hypertension and / or heart failure,cerebrovascular diseases blood diseases of unknown etiology (leukopenia and anemia) severe somatic diseases dyslipidemia / hyperlipidemia diabetes mellitus peripheral arterial disease the simultaneous use of drugs that can increase the risk of ulcers or bleeding, in particular, oral corticosteroids (including prednisolone), anticoagulants (including warfarin), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline) or antiplatelet agents (including acetylsalicylic acid, clopidogrel) in the I and II trimesters of pregnancy, during breastfeeding elderly patients, patients under the age of 12 when smoking, frequent alcohol consumption.severe somatic diseases dyslipidemia / hyperlipidemia diabetes mellitus peripheral arterial disease the simultaneous use of drugs that can increase the risk of ulcers or bleeding, in particular, oral corticosteroids (including prednisolone), anticoagulants (including warfarin), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline) or antiplatelet agents (including acetylsalicylic acid, clopidogrel) in the I and II trimesters of pregnancy, during breastfeeding elderly patients, patients under the age of 12 when smoking, frequent alcohol consumption.severe somatic diseases dyslipidemia / hyperlipidemia diabetes mellitus peripheral arterial disease the simultaneous use of drugs that can increase the risk of ulcers or bleeding, in particular, oral corticosteroids (including prednisolone), anticoagulants (including warfarin), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline) or antiplatelet agents (including acetylsalicylic acid, clopidogrel) in the I and II trimesters of pregnancy, during breastfeeding elderly patients, patients under the age of 12 when smoking, frequent alcohol consumption.which can increase the risk of ulcers or bleeding, in particular, oral corticosteroids (including prednisolone), anticoagulants (including warfarin), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline) or antiplatelet agents (including acetylsalicylic acid, clopidogrel) in the I and II trimesters of pregnancy, during breastfeeding elderly patients, patients under the age of 12 when smoking, frequent alcohol consumption.which can increase the risk of ulcers or bleeding, in particular, oral corticosteroids (including prednisolone), anticoagulants (including warfarin), selective serotonin reuptake inhibitors (including citalopram, fluoxetine, paroxetine, sertraline) or antiplatelet agents (including acetylsalicylic acid, clopidogrel) in the I and II trimesters of pregnancy, during breastfeeding elderly patients, patients under the age of 12 when smoking, frequent alcohol consumption.period of breastfeeding elderly patients, patients under the age of 12 when smoking, frequent alcohol consumption.period of breastfeeding elderly patients, patients under the age of 12 when smoking, frequent alcohol consumption.
Specifications
Category
Pain relievers
,
Migraine
,
Pain and fever
Scope of the drug
General
Release form
Tablet
Manufacturer country
Great Britain
Package quantity, pcs
twenty
Vacation conditions
Without recipe
Brand name
Nurofen
The amount of the dosage form in the primary package
10 pieces.
Primary packaging type
Blister
Type of consumer packaging
Pack of cardboard
Pharmaco-therapeutic group
NSAIDs
Anatomical and therapeutic characteristics
M01AE01 Ibuprofen
Dosage form
Film-coated tablets
Expiration date in days
1095
Package weight, g
twenty
Mode of application
:
For oral administration. Patients with hypersensitivity of the stomach are advised to take the drug with meals. For short term use only. Read the instructions carefully before taking the drug. Adults and children over 12 years old: by mouth 1 tablet (200 mg) up to 3-4 times a day. The tablets should be taken with water. To achieve a faster therapeutic effect in adults, the dose can be increased to 2 tablets (400 mg) up to 3 times a day. Children from 6 to 12 years old: 1 tablet (200 mg) up to 3-4 times a day the drug can be taken only if the child's body weight is more than 20 kg. The interval between pills should be at least 6 hours. The maximum daily dose for adults is 1200 mg (6 tablets). Maximum daily dose for children from 6 to 18 years old: 800 mg (4 tablets).If, after taking the drug for 2-3 days, the symptoms persist or worsen, you must stop treatment and consult a doctor.
Information on technical characteristics, delivery set, country of manufacture "